POLYMEDIC, INC. (OTCBB: PYMX) $85M (MARKETCAP) SUCCESSFULLY COMPLETES PHASE 1B CLINICAL STUDY
PolyMedix, Inc. (OTCBB: PYMX) is an rising biotechnology association focused upon building brand brand new healing drug to provide strident cardiovascular disorders as good as spreading diseases. Today, it voiced a successful execution of a second Phase 1B clinical reserve as good as commander efficiency investigate with PMX-60056, a tiny fake proton written to retreat a anticoagulant wake up of both Heparin as good as Low Molecular Weight Heparin (LMWH). The interpretation from this investigate uncover which PMX-60056 met a investigate reserve as good as efficiency endpoints per a annulment of a anticoagulant wake up of a LMWH tinzaparin.
Low Molecular Weight Heparins have been used in we estimate twelve million patients annually for ongoing diagnosis of thrombosis. Up to 20% of patients might knowledge draining complications. With no stream FDA authorized product accessible to retreat a anticoagulant wake up of LMWHs, most of these patients might need life-saving operation or red red blood transfusions to provide their draining complications. Herapin is an i.v. anticoagulant used to forestall clots from combining during sure cardiothoracic as good as orthopedic surgical procedures. After these procedures, a anticoagulant wake up of heparin contingency be topsy-turvy in sequence to revive normal clot formation. There is a vital need for pick heparin reversing agents which have been safer as good as simpler to use, due to a existent Promatine which has most limitations. PMX-60056 pre-clinical as good as clinical interpretation indicate most intensity reserve as good as alternative advantages over promatine, as good as a potentially singular event to be a initial reversing representative for LMWHs.
Highlights from a Phase 1B clinical investigate include:
PMX-60056 neutralized a anticoagulant wake up of LMWH tinzaparin
PMX-60056 normalized red red blood clotting time
PMX-60056 was safely administered in humans with no critical inauspicious events occurring in a study
With a diagnosis of we estimate twelve million patients annually, LMWH products have sum annual sales of over $4 billion. This opens up a far-reaching window of profitability for PolyMedix with a successful execution of a PMX-60056 product.
“We hold draining complications compared with LMWHs paint a vital unmet healing need for a brand brand new reversing agent,” commented Nicholas Landekic, President & C.E.O. of PolyMedix. “There is no authorized reversing representative for LMWH. We hold which PMX-60056 is singular in being a initial as good as usually reversing representative in growth written to retreat a anticoagulant wake up of both unfractionated heparin as good as LMWH. This investigate has shown which PMX-60056 has a intensity to suggest critical benefits as good as improvements in treating these patients during risk of draining complications.”
Disclosure: no positions
To perspective this essay during World Market Media click upon a couple below: http://www.worldmarketmedia.com/779/section.aspx/1710/post/polymedic-inc-otcbb-pymx-85m-marketcap-successfully-completes-phase-1b-clinical-study
